(E)-2-methyl-N-((5-methyl-1H-pyrazol-4-yl)methylene)propane-2-sulfinamide | 1027329-44-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-2-methyl-N-((5-methyl-1H-pyrazol-4-yl)methylene)propane-2-sulfinamide
• 英文别名: (NE)-2-methyl-N-[(5-methyl-1H-pyrazol-4-yl)methylidene]propane-2-sulfinamide
• CAS: 1027329-44-7
• 化学式: C₉H₁₅N₃OS
• 分子量: 213.304
• InChiKey: SGMRADNZPJGFBY-IZZDOVSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  77.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-2-methyl-N-((5-methyl-1H-pyrazol-4-yl)methylene)propane-2-sulfinamide 、 甲基溴化镁 在 氯化铵 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 以67%的产率得到2-methyl-N-(1-(5-methyl-1H-pyrazol-4-yl)ethyl)propane-2-sulfinamide
  参考文献：
  名称：

  [EN] SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS
  [FR] COMPOSÉS BICYCLOCARBOXYAMIDES SUBSTITUÉS

  摘要：

  公开号：

  WO2008059370A8

文献信息

• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2013046136A1

  公开（公告）日：2013-04-04

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formual (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式(I)的化合物或其药学上可接受的盐，其中R1-R6在此处被定义。该发明还涉及含有公式(I)化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式(I)的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• Substituted bicyclocarboxyamide compounds
  申请人：Pfizer Inc.

  公开号：US07964732B2

  公开（公告）日：2011-06-21

  This invention provides a compound of the formula These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个公式的化合物。这些化合物对于治疗由VR1受体过度激活引起的疾病状况，例如哪些在哺乳动物中引起疼痛等方面是有用的。该发明还提供了包括上述化合物的制药组合物。
• Substituted Bicyclocarboxyamide Compounds
  申请人：Ando Koji

  公开号：US20100267769A1

  公开（公告）日：2010-10-21

  This invention provides a compound of the formula These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一个化合物的公式，该化合物对于治疗由VR1受体过度活化引起的疾病状态，如哮喘等哺乳动物中的疼痛等疾病状态非常有用。本发明还提供了一种包含上述化合物的药物组合物。
• SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS
  申请人：Pfizer Inc.

  公开号：EP2091944B1

  公开（公告）日：2011-05-18